The Organic Chemistry of Drug Synthesis, Volume 7

Informationen zum Autor DANIEL LEDNICER, PHD, is the author of several books on drug synthesis and discovery. His career in both the private and public sectors has been devoted to the search for new therapeutic agents. Dr. Lednicer spent two decades at the bench as a chemist at the Upjohn Company. Following that, he served as director of chemical research at Mead Johnson, director of pharmaceutical sciences at Adria Laboratories, and pharmaceutical manager at Analytical Biochemistry Laboratories. Most recently, he was a project officer at the National Cancer Institute. Klappentext THE CLASSIC REFERENCE ON THE SYNTHESIS OF MEDICINAL AGENTS --NOW COMPLETELY UPDATED The seventh volume in the definitive series that provides a quick yet thorough overview of the synthetic routes used to access specific classes of therapeutic agents, this volume covers approximately 220 new non-proprietary drug entities introduced since the publication of Volume 6. Many of these compounds represent novel structural types first identified by sophisticated new cell-based assays. Specifically, a significant number of new antineoplastic and antiviral agents are covered. As in the previous volumes, materials are organized by chemical class and syntheses originate with available starting materials. Organized to make the information accessible, this resource covers disease state, rationale for method of drug therapy, and the biological activities of each compound and preparation. The Organic Chemistry of Drug Synthesis, Volume 7 is a hands-on reference for medicinal and organic chemists, and a great resource for graduate and advanced undergraduate students in organic and medicinal chemistry. Zusammenfassung The Organic Chemistry of Drug Synthesis! Volume 7 focuses on the synthetic aspects of the pharmaceutical industry. The synthetic routes and strategies devised to prepare a pharmaceutically active agent are discussed in detail! utilizing common current drugs as examples. ...

Autorentext
DANIEL LEDNICER, PHD, is the author of several books on drug synthesis and discovery. His career in both the private and public sectors has been devoted to the search for new therapeutic agents. Dr. Lednicer spent two decades at the bench as a chemist at the Upjohn Company. Following that, he served as director of chemical research at Mead Johnson, director of pharmaceutical sciences at Adria Laboratories, and pharmaceutical manager at Analytical Biochemistry Laboratories. Most recently, he was a project officer at the National Cancer Institute.

Klappentext
THE CLASSIC REFERENCE ON THE SYNTHESIS OF MEDICINAL AGENTS --NOW COMPLETELY UPDATED The seventh volume in the definitive series that provides a quick yet thorough overview of the synthetic routes used to access specific classes of therapeutic agents, this volume covers approximately 220 new non-proprietary drug entities introduced since the publication of Volume 6. Many of these compounds represent novel structural types first identified by sophisticated new cell-based assays. Specifically, a significant number of new antineoplastic and antiviral agents are covered. As in the previous volumes, materials are organized by chemical class and syntheses originate with available starting materials. Organized to make the information accessible, this resource covers disease state, rationale for method of drug therapy, and the biological activities of each compound and preparation. The Organic Chemistry of Drug Synthesis, Volume 7 is a hands-on reference for medicinal and organic chemists, and a great resource for graduate and advanced undergraduate students in organic and medicinal chemistry.

Zusammenfassung
The Organic Chemistry of Drug Synthesis, Volume 7 focuses on the synthetic aspects of the pharmaceutical industry. The synthetic routes and strategies devised to prepare a pharmaceutically active agent are discussed in detail, utilizing common current drugs as examples.

Inhalt
Preface. 1 OPEN-CHAIN COMPOUNDS. 1. Human Immunodeficiency Virus. 2. Human Rhinovirus. 2 ALICYCLIC COMPOUNDS. 1. Monocyclic Compounds. 2. Polycyclic Compounds: Steroids. 3. Polycyclic Compounds. 3 MONOCYCLIC AROMATIC COMPOUNDS 1. Arylcarbonyl Derivatives. 2. Biphenyls. 3. Compounds Related to Aniline. 4. Compounds Related to Arylsulfonic Acids. 5. Diarylmethanes. 6. Miscellaneous Monocyclic Aromatic Compounds. 4 CARBOCYCLIC COMPOUNDS FUSED TO A BENZENE RING. 1. Indenes. 2. Naphthalenes. 3. Tetrahydronaphthalenes. 4. Other benzofused carbocyclic compounds. 5 FIVE-MEMBERED HETEROCYCLES. 1. Compounds with One Heteroatom. 2. Compounds with Two Heteroatoms. 6 SIX-MEMBERED HETEROCYCLES. 1. Compounds with One Heteroatom. 2. Compounds with Two Heteroatoms. 7 FIVE-MEMBERED HETEROCYCLES FUSED TO ONE BENZENE RING. 1. Compounds with One Heteroatom. 2. Five-Membered Rings with Two Heterocyclic Atoms. 8 SIX-MEMBERED HETEROCYCLES FUSED TO ONE BENZENE RING. 1. Compounds with One Heteroatom. 2. Compounds with Two Heteroatoms. 9 BICYCLIC FUSED HETEROCYCLES. 1. Compounds with Five-Membered Rings Fused to Six-Membered Rings. 2. Compounds with Two Fused Six-Membered Rings. 3. Miscellaneous Compounds with Two Fused Heterocyclic Rings: Beta Lactams. 10 POLYCYCLIC FUSED HETEROCYCLES. 1. Compounds with Three Fused Rings. 2. Compounds with Four Fused Rings. 3. Compounds with Five or More Fused Rings: Camptothecins. References. Subject Index. Cross Index of Biological Activity. Cumulative Index.

#	Onlineshop	Preis CHF	Versand CHF	Total CHF
1	Seller	0.00	0.00	0.00